The AVENIO ctDNA Targeted Kit is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC). The AVENIO ctDNA Targeted Kit is an efficient tumor profiling solution.
Features and Benefits of AVENIO ctDNA Targeted Kit
Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
Includes reagents, bioinformatics and software
Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
Overview
The AVENIO ctDNA Targeted Kit is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC). The AVENIO ctDNA Targeted Kit is an efficient tumor profiling solution.
Features and Benefits of AVENIO ctDNA Targeted Kit
Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
Includes reagents, bioinformatics and software
Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
Product Highlights
Accurate detection of all four mutation classes with high sensitivity and specificity2,3
>99% sensitivity for SNVs, indels, CNVs, and fusions
>99% positive predictive value (PPV) for all classes of mutations
View the detailed Gene List for the AVENIO Targeted Panel
The Unique Challenges and Opportunities of Circulating Tumor DNA
Presenter: Dan Klass, Ph.D.
Roche
The AVENIO family of NGS oncology assays
The AVENIO ctDNA Targeted Kit is a part of the AVENIO family of NGS oncology assays that include three ctDNA and three corresponding tumor tissue assays. By using the wider family of AVENIO assays, labs can obtain detailed molecular findings across all four mutation classes from plasma or tissue samples.